The cancer risk of chronic intranasal IGF2 administration is likely to be low, as well; 1 year of daily intranasal administration of insulin, which is also a mitogenic peptide, did not increase cancer incidence in a large clinical trial.183. This evidence concerns the gene INS and cancer.